Abstract Details
|
Julio C. Rojas-Martinez, MD, PhD
(UCSF)
PRESENTER |
Dr. Rojas-Martinez has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ferrer International, S.A.. The institution of Dr. Rojas-Martinez has received research support from NIH/NIA. The institution of Dr. Rojas-Martinez has received research support from Eli Lilly. The institution of Dr. Rojas-Martinez has received research support from Eisai. The institution of Dr. Rojas-Martinez has received research support from Amylyx. |
| No disclosure on file | |
| Jon Elofson | No disclosure on file |
| Ignacio Illan-Gala, Sr., MD, PhD (Hospital de la Santa Creu i Sant Pau) | Dr. Illan-Gala has nothing to disclose. |
| Howard J. Rosen, MD (UCSF) | Dr. Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly . Dr. Rosen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alector. The institution of Dr. Rosen has received research support from NIH. The institution of Dr. Rosen has received research support from State of CA. Dr. Rosen has a non-compensated relationship as a Consultant with Prevail Therapeutics that is relevant to AAN interests or activities. Dr. Rosen has a non-compensated relationship as a consultant with Alchemab that is relevant to AAN interests or activities. |
| Michael D. Geschwind, MD, PhD, FAAN (UCSF) | Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Brainstorm Cell Therapeutics, Inc.. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Walter Grubb. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gerson Lehrman Group. Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Reata Pharmaceuticals, Inc.. |